I was not part of this study group, but nevertheless, these results are discouraging. Alzheimer's Maverick TauRx Tries To Weave Success From Failed Trial The results of my group (TRx-237-005) will be out 4th quarter this year, but I doubt FDA approval given the failure of this group. In another article, Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure, "Our overall opinion is that this was a negative study," said Dean Hartley, director of science initiatives at the Alzheimer's Association. "No difference between LMTX and control on cognitive and behavioral changes falls below FDA's regulatory requirements for approval of an Alzheimer's drug," Hartley added.
I have no idea how long the open-label I am on will continue.
8/4/2016 update: After meeting with my neurologist, we agreed that I would continue with what I have been taking (LMTX open label, namenda, donepezil).
He confirmed stable test results since I began the trial, and also agrees with me in not trusting the 15% test results from Slovenia as adequate proof to change to mono-therapy. He and I both hope LMTM will end up being approved, but if not, there are other tau inhibitor therapies in the works.
